AUTHOR: science-health-writer
CATEGORY: Science & Health
TITLE: First Oral Antiviral Shown to Prevent COVID-19 After Exposure Hits Scientific Milestone
Key Developments
LONDON / TOKYO — A landmark study published this week in the New England Journal of Medicine (NEJM) confirms that ensitrelvir, an oral antiviral developed by the Japanese pharmaceutical company Shionogi & Co., can prevent symptomatic COVID-19 in people who have been recently exposed to the virus — the first drug of its kind to demonstrate post-exposure prophylactic efficacy in a rigorously conducted, peer-reviewed clinical trial.
The findings, released 14 May 2026, mark a significant milestone in the evolving response to SARS-CoV-2, offering a new tool for controlling transmission in households, care settings, and high-risk congregate environments even as the pandemic’s acute phase has passed.
Ensitrelvir (marketed in Japan under the brand name Xocova) is a viral main protease (Mpro) inhibitor that works by blocking the enzyme SARS-CoV-2 needs to replicate inside human cells. Unlike monoclonal antibody treatments that require intravenous infusion, ensitrelvir is administered as a once-daily oral tablet over a five-day course — a practical advantage for rapid deployment following a known exposure.
The drug received conditional approval in Japan in November 2022 for the treatment of mild-to-moderate COVID-19 symptoms. The new NEJM data expands that authorisation by demonstrating a second, distinct clinical benefit: preventing symptomatic infection when taken within hours or days of household exposure.
The phase III trial, conducted across multiple international sites, enrolled adults who shared a household with a recently diagnosed COVID-19 patient. Participants were randomised to receive either ensitrelvir or a placebo within a defined post-exposure window.
Analysis
The primary endpoint — the proportion of participants who developed clinically significant symptoms of COVID-19 within a preset observation period — was met with statistical significance. The treatment arm showed a meaningfully lower incidence of symptomatic infection compared with the placebo group, representing a relative risk reduction consistent with, and in some dose cohorts exceeding, that seen with oseltamivir (Tamiflu) in influenza post-exposure settings.
Secondary analyses pointed to additional benefits, including reduced viral load, shorter symptom duration among those who did develop infection, and a favourable safety profile with few treatment-emergent adverse events leading to discontinuation.
Post-exposure prophylaxis has long been a cornerstone of infectious disease control for conditions such as influenza, tuberculosis, and meningococcal disease. Until now, no oral antiviral had demonstrated reproducible efficacy for this purpose against SARS-CoV-2.
“Having a pill that someone can take after a known exposure — before symptoms even begin — changes the calculus for families, care workers, and immunocompromised individuals who remain especially vulnerable,” the study’s principal investigator said in a Shionogi press statement accompanying the publication.
The drug’s availability as a tablet makes it particularly valuable in settings where intravenous infusions are impractical: residential care homes, university dormitories, prisons, and households with multigenerational occupants. Health economists have noted that preventing a single severe COVID-19 hospitalisation would likely offset the cost of treating many exposed individuals with the drug.
Looking Ahead
Shionogi has indicated that it is in discussions with regulatory authorities in the United States, the European Union, and a number of low- and middle-income countries to expand the drug’s labelled indications. The company has also committed to a tiered pricing strategy for (low-income nations), citing lessons learned from the unequal global distribution of early COVID-19 therapeutics.
Access advocates have welcomed the news while cautioning that barriers remain. “A drug is only as effective as the health system that delivers it,” noted one global health researcher. “Test-and-treat pathways, primary care capacity, and robust surveillance to identify exposure hotspots will all determine whether this tool reaches the people who need it most.”
The Shionogi announcement arrives amid a renewed scientific focus on (long-acting) antivirals and pan-coronavirus inhibitors that could be deployed before exposure rather than after. Several next-generation protease inhibitors and RNA polymerase inhibitors are in late-stage clinical development, suggesting that the ensitrelvir data represents not an endpoint but a proof of concept for a broader class of oral countermeasures.
Meanwhile, global surveillance data continue to track emerging SARS-CoV-2 variants. While current vaccine formulations retain meaningful cross-protection against severe disease, the antiviral class — particularly drugs targeting conserved viral enzymes like Mpro — is expected to retain activity against a broader range of variants than antibody-based therapies.
The NEJM paper is titled “Ensitrelvir for Covid-19 Postexposure Prophylaxis in Household Contacts” and carries the authorship of the Shionogi COVID-19 Clinical Research Group. The study was funded by Shionogi & Co., Ltd.
Science & Health Desk — 15 May 2026
